TOVX therivabio.com: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

The price action of Theriva Biologics, Inc. (TOVX) reflects an EV/EBITDA of 0.00, while the company finances the development of anti-tumor viruses through grants. The brand's high scientific potential enables the development of protein blocking methods for gastrointestinal tract treatment. To eliminate human error during culture growth, automated bioreactors in sterile booths are being implemented, minimizing the risk of medium contamination.
פילוחי נתונים אנליטיים מרוכזים עבור Synthetic Biologics (TOVX)

To isolate fundamental stability from market noise, it is necessary to use a metric that compares the total enterprise value (including debt) of Theriva Biologics, Inc. (TOVX) with its operating profit before interest, taxes, depreciation, and amortization. This ratio determines the real value of assets relative to the generated cash flow, making it possible to identify overvaluation or stagnation within the company. By analyzing the EV/EBITDA valuation trend, an investor can assess the efficiency of attracting venture capital to overcome stringent FDA regulatory barriers during the development of oncolytic viruses.